Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by stockman6767on Jan 15, 2015 10:13am
259 Views
Post# 23322648

Global Kidney Fibrosis Treatment Market Share,Size Analysis

Global Kidney Fibrosis Treatment Market Share,Size Analysis Global Kidney Fibrosis Treatment Market Share,Size Analysis and Forecast to 2020, By Persistence Market Research
https://www.whatech.com/market-research-reports/press-release/medical/39028-global-kidney-fibrosis-treatment-market-share-size-analysis-and-forecast-to-2020-by-persistence-market-research


Kidney fibrosis may be caused due to disease in kidney. It may be any stage from chronic kidney disease (CKD) to end-stage renal disease (ESRD).

In this condition, kidneys stop working and gradually require transplantation. Various medications that are available in the market for treatment of kidney fibrosis are Renin inhibitors, Vasopeptidase inhibitors, Angiotensin II receptor blockers (ARBs), Angiotensin-converting enzyme (ACE) inhibitors and Pirfenidones.

Increasing prevalence of kidney diseases and no other alternative treatment available is driving the market for kidney fibrosis treatment.

 

North America, followed by the Europe, dominates the global market for kidney fibrosis due to large number of aging population and better healthcare facilities available in the region. In addition, there is high prevalence of kidney diseases in the region.

According to The Centers for Disease Control and Prevention (CDC), a public health institute in 2014, in the U.S., it is estimated that more than 20 million people are suffering from chronic kidney disease. Asia is expected to show high growth rate in the next few years in global kidney fibrosis treatment market.

China and India are expected to be the fastest kidney fibrosis market in Asia region. Some of the key driving forces for kidney fibrosis market in emerging countries are increasing R&D investment, large pool of patients, rising government funding and growing level of awareness.

Buy Full Report: https://www.persistencemarketresearch.com/market-research/kidney-fibrosis-treatment-market.asp

Diseases such as obesity accelerate the incidence of kidney fibrosis. In addition, habits such smoking also adds to increment in incidence of kidney fibrosis.

Increasing patient pool, rising awareness about treatment of kidney diseases and government funding are some of the key factors driving the kidney fibrosis market. In addition, introduction of safer and effective therapeutics for the treatment of kidney fibrosis is driving the market.

However, high cost involved and no success for all the cases is restraining the kidney fibrosis market.

Introduction of the concept of personalized medicines, mono-therapeutic approaches or combination of therapies are expected to offer good opportunities for kidney fibrosis market. In addition, introduction statins for, which are related to lowering of lipid content, thus expected to be an efficient treatment for kidney scarring.

Growing demographics and economies in the developing countries such as India and China in Asia and other countries in South East Asia, Latin America and Middle East are expected to offer high growth in kidney fibrosis treatment market. One of the major trends that have been observed in kidney fibrosis treatment market includes various pharmaceutical and biotechnology companies involved in R&D of some novel medications for the treatment of kidney fibrosis.

Some of the key companies dealing in kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Pfizer, Inc, La Jolla Pharmaceutical Company, Merck & Co., InterMune, Inc.

and Galectin Therapeutics, Inc. Other companies dealing the kidney fibrosis treatment market which have significant presence are Genzyme Corporation, ProMetic Life Sciences Inc.

and BioLineRx, Ltd.

Request Full TOC: https://www.persistencemarketresearch.com/toc/3102

Bullboard Posts